Navigation Links
CV Therapeutics to Host Investor Science Day on Thursday, February 7, 2008
Date:1/31/2008

PALO ALTO, Calif., Jan. 31 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) today announced that it will host an Investor Science Day for the financial community in New York City on Thursday, February 7, 2008 beginning at 9:00 a.m. EST.

The event will be webcast live and available for replay on the company's Web site, http://www.cvt.com.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics' clinical and preclinical drug development candidates and programs include regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies, and CVT-6883, which is being developed as a potential treatment for cardiopulmonary diseases. Regadenoson and CVT-6883 have not been determined by any regulatory authorities to be safe or effective in humans for any use.

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncer
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
2. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
3. CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008
4. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
5. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
6. Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
8. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
9. Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors
10. Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
11. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... , July 27, 2015 The ... announced the winners of its annual Klerman and ... by scientists who have been supported by NARSAD ... scientists to pursue innovative ideas in neurobiological and ... of concept for the early detection, treatment, prevention ...
(Date:7/26/2015)... ... July 26, 2015 , ... Maine Standards ... verification / linearity test kit. The VALIDATE® ANEMIA kit contains Ferritin, Folate, and ... prepared using the CLSI recommended “equal delta” method for linearity testing and is ...
(Date:7/24/2015)... , July 24, 2015 ... equities: PDL BioPharma Inc. (NASDAQ: PDLI ), Arena ... STEM ), Northwest Biotherapeutics Inc. (NASDAQ: NWBO ... Free research report on PDL BioPharma can be accessed ... the NASDAQ Composite ended at 5,146.41, down 0.49%, the ...
(Date:7/24/2015)... -- The global next generation sequencing ... by 2022, growing at an estimated CAGR of 40.1% ... by Grand View Research, Inc. Development of faster, more ... significant reduction in cost of sequencing one base pair. ... of next generation sequencing throughout the forecast period. Revenue ...
Breaking Biology Technology:Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 4Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 5Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 6Maine Standards Company, LLC Announces Release of VALIDATE® ANEMIA Calibration Verification / Linearity Test Kit 2Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 2Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 3Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 4Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 5Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 2Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 3Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 4Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 5
... Polymer nano-films and nano-composites are used in a ... sports equipment to automotive and aerospace applications. Thermal ... these applications, but the growing trend to use ... In recent years an atomic force microscope-based ...
... N.J., Jan. 12, 2012 NeoStem,s cell therapy ... Inc. company (NYSE Amex: NBS ) ... whereby PCT will provide contract manufacturing and regulatory ... – PTM, which will be an injectable suspension ...
... the way pavement, softened by a hot sun, will ... with wondrous propertiesslows down an object sliding across its ... slippery, say theorists at the National Institute of Standards ... the material,s friction. "I don,t think anyone expects ...
Cached Biology Technology:Magnetic actuation enables nanoscale thermal analysis 2Islet Sciences, Inc. Selects NeoStem's Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing 2Islet Sciences, Inc. Selects NeoStem's Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing 3Islet Sciences, Inc. Selects NeoStem's Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing 4Slippery when stacked: NIST theorists quantify the friction of graphene 2
(Date:7/20/2015)... DENVER , July 20, 2015  Acuity ... Mobility Report: The Convergence of Commerce and Privacy" ... billion mobile biometric apps will be downloaded to ... users. The mobile biometrics market is projected to ... app revenue during the seven-year forecast period.    ...
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 30, 2015 after the close of market. The company ... investors at 2:00 p.m. PT (5:00 p.m. ET), during ... To participate on the live call, analysts and investors ...
(Date:7/9/2015)... JOSE, Calif. , July 9, 2015 ... the leading developer of human interface solutions, ... technology, the industry,s first fully hardware encapsulated ... Match-in-Sensor secure authentication technology is literally off ... storage and biometric matching within the fingerprint ...
Breaking Biology News(10 mins):Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... LEDs to light UT arena . . . ... the University of Tennessee,s Thompson-Boling Arena will become the ... smaller, brighter and up to 85 percent more efficient ... fixtures developed by Oak Ridge-based LED North America incorporate ...
... peninsula of 11,500 km2 within the Arabian Peninsula. Both ... last decades, thus putting a strong pressure on native ... development has triggered a variety of studies of its ... confirmed the occurrence of 21 lizard species, two of ...
... bone marrow cells to deliver potentially curative gene therapy ... syndrome an often fatal condition that causes organ ... Children,s Hospital Medical Center and the National Institute of ... for treating the disease the week of Feb. 3-7 ...
Cached Biology News:Story tips from the Department of Energy's Oak Ridge National Laboratory, February 2014 2Story tips from the Department of Energy's Oak Ridge National Laboratory, February 2014 3Where do lizards in Qatar live? First distribution maps for the state 2Mouse study shows gene therapy may be possible cure for Hurler syndrome 2
... Kit measures adenosine triphosphate (ATP) ... a dynamic range. Based on ... measures ATP in bacterial, plant ... concentration range of 10-11 to ...
... of refrigerated cold traps offers a choice ... volatility/aqueous solvents or high volatility solvents. Ideal ... concentrators/centrifugal evaporators. Also used for maintaining vapor-free ... used in electron microscopes. Can be used ...
... Trap is specifically designed for efficient ... as DMSO and DMF in the ... refrigeration system set at -5 o ... DMSO, while completely eliminating the risk ...
Black 96 Well Plate EB, RE Bottom...
Biology Products: